Interní Med. 2007; 9(1): 11-13

Metabolic syndrome and myomas of uterus

doc. MUDr. Alena Šmahelová Ph.D1, MUDr. Jana Náteková2
1 Klinika gerontologická a metabolická, FN Hradec Králové
2 Porodnická a gynekologická klinika, LF UK a FN v Hradci Králové

Depending on the used definition metabolic syndrome is present in up to one third of adult population. It is a very frequent disease; at least one of its components is present in almost 80% of adults. It has important relation to gynecology, both direct (mainly in polycystic ovary syndrome) and indirect (malignancies, gestational diabetes, perioperative periods). Hyperinsulinism, diabetes and obesity are important factors discussed in pathogenesis of tumors in general, including gynecological ones. In spite of some clear relations of metabolic syndrome to intestinal, renal, urinary bladder and breast tumors, relation of metabolic syndrome and prevalence of benign gynecological tumors – myomas is unclear. Metabolic syndrome is a cause of high morbidity and mortality as a consequence of clinical presentation of atherosclerosis. However it is not excluded that some components of dyslipidemy might have even a protective effect.

Keywords: Key words: metabolic syndrome, gynecological tumors, myomas of uterus.

Published: January 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šmahelová A, Náteková J. Metabolic syndrome and myomas of uterus. Interní Med. 2007;9(1):11-13.
Download citation

References

  1. Bachmann GA. Hysterectomy: a critical review. J Reprod Med. 1990; 35: 839-862. Go to PubMed...
  2. Balkau B, et al. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab, 2002, Nov; 28 (5): 364-76. Reaven GM. Role of insulin resistance in human disease. Diabetes, 1988; 37: 1595-1607. Go to original source... Go to PubMed...
  3. Buttram VC, Reiter RC. Uterine leiomyomata - aetiology, symptomatology and management. Rertil Steril, 1981; 36: 433-445. Go to original source... Go to PubMed...
  4. Faerstein E, Szklo M, Rosenshein NB. Risk factors for uterine leiomyoma: A practice-based case-control study. II. Atherogenic risk factors and potential sources of uterine irritation. Am J Epidemiol 2001; 153: 11-19. Go to original source... Go to PubMed...
  5. Friedman AJ, Harrison-Atlas D, Barbieri RL, et al. A randomized, placebo-controlled, double - blinded study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomatal. Fertil Steril, 1989; 51: 251-256. Go to original source... Go to PubMed...
  6. Greenberg MD, Kazamel TIG. Medical and socioeconomic impact ofuterine fibrods. Obstetrics and gynecology Clinics of North America. 1995; 22: 625-636. Go to original source... Go to PubMed...
  7. Holub Z, Kužel D, Kučera E, Eim J, Novotný Z, Hanousek L, Machač J. Management děložních myomů: CSGE doporučení k provádění správné klinické praxe. Česká gynekologie, 70, 2005; 2: 165-168.
  8. Luoto R, Rutanen E, Auvinen A. Fibroids and hypertension. A cross-sectional study of women undergoing hysterectomy. J Reprod Med 2001; 46: 359-364. Go to PubMed...
  9. NCEP Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III (ATP III), May, 2001.
  10. Parazzini F, Chiaffarino F, Polverino G, Chiantera V, Surace M, La Vecchia C. Uterine fibroid risk and history of selected medical conditions linked with female hormones. Eur J Epidemiol 2004; 19: 249-253. Go to original source... Go to PubMed...
  11. Reaven GM. Role of insulin resistance in human disease. Diabetes, 1988; 37: 1595-1607. Go to original source... Go to PubMed...
  12. Ross RK, Pike MC, Vessey MP, et al. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br Med J, 1986; 293: 359-363. Go to original source... Go to PubMed...
  13. Svačina Š, a kol. Metabolický syndrom. Triton, Praha, 2006: 282 s.
  14. Vessey MP, Villard-Mackintosh L, Mc Pherson K, et al. The epidemiology of hysterectomy: findings in a large cohort study. Br. J. Obstet. Gynaecol., 1992; 99: 402-407. Go to original source... Go to PubMed...
  15. Vollenhoven B. Introduction: the epidemiology of uterine leimyomas. Bailliere's Clin Obstet Gynaecol. 1998; 12: 169-176. Go to original source... Go to PubMed...
  16. Wallach EE, Vlahos NF: Uterine myomas: An overview of development, clinical features, and management. Obstetrics and gynecology, 2004; 104 (2): 393-406. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.